143 related articles for article (PubMed ID: 8372162)
21. Delayed peak latency of the mismatch negativity in schizophrenics and alcoholics.
Kathmann N; Wagner M; Rendtorff N; Engel RR
Biol Psychiatry; 1995 May; 37(10):754-7. PubMed ID: 7640331
[No Abstract] [Full Text] [Related]
22. The P50 auditory evoked potential in violent and non-violent patients with schizophrenia.
Fresán A; Apiquian R; García-Anaya M; de la Fuente-Sandoval C; Nicolini H; Graff-Guerrero A
Schizophr Res; 2007 Dec; 97(1-3):128-36. PubMed ID: 17936591
[TBL] [Abstract][Full Text] [Related]
23. P300, clinical symptoms, and neuropsychological parameters in acute and remitted schizophrenia: a preliminary report.
Eikmeier G; Lodemann E; Zerbin D; Gastpar M
Biol Psychiatry; 1992 May; 31(10):1065-9. PubMed ID: 1511077
[No Abstract] [Full Text] [Related]
24. Memory impairment and auditory evoked potential gating deficit in schizophrenia.
Hsieh MH; Liu K; Liu SK; Chiu MJ; Hwu HG; Chen AC
Psychiatry Res; 2004 Feb; 130(2):161-9. PubMed ID: 15033186
[TBL] [Abstract][Full Text] [Related]
25. Contributions of subtype and spectral frequency analyses to the study of P50 ERP amplitude and suppression in schizophrenia.
Johannesen JK; Kieffaber PD; O'Donnell BF; Shekhar A; Evans JD; Hetrick WP
Schizophr Res; 2005 Oct; 78(2-3):269-84. PubMed ID: 16002265
[TBL] [Abstract][Full Text] [Related]
26. Measurement of maximum variability within event related potentials in schizophrenia.
Anderson J; Rennie C; Gordon E; Howson A; Meares R
Psychiatry Res; 1991 Oct; 39(1):33-44. PubMed ID: 1685249
[TBL] [Abstract][Full Text] [Related]
27. Lack of relationship of auditory gating defects to negative symptoms in schizophrenia.
Adler LE; Waldo MC; Tatcher A; Cawthra E; Baker N; Freedman R
Schizophr Res; 1990; 3(2):131-8. PubMed ID: 2278977
[TBL] [Abstract][Full Text] [Related]
28. Is P50 suppression a measure of sensory gating in schizophrenia?
Jin Y; Bunney WE; Sandman CA; Patterson JV; Fleming K; Moenter JR; Kalali AH; Hetrick WP; Potkin SG
Biol Psychiatry; 1998 Jun; 43(12):873-8. PubMed ID: 9627741
[TBL] [Abstract][Full Text] [Related]
29. Auditory event-related potentials, auditory digit span, and clinical symptoms in chronic schizophrenic men on neuroleptic medication.
Stefánsson SB; Jónsdóttir TJ
Biol Psychiatry; 1996 Jul; 40(1):19-27. PubMed ID: 8780851
[TBL] [Abstract][Full Text] [Related]
30. Negative difference (Nd), an ERP marker of stimulus relevance: different lateral asymmetries for paranoid and nonparanoid schizophrenics.
Oades RD; Zerbin D; Eggers C
Pharmacopsychiatry; 1994 Mar; 27(2):65-7. PubMed ID: 8029314
[TBL] [Abstract][Full Text] [Related]
31. Influence of stimulation parameters on auditory stimulus processing in schizophrenia and major depression: an auditory evoked potential study.
Adler G; Adler J; Schneck M; Armbruster B
Acta Psychiatr Scand; 1990 May; 81(5):453-8. PubMed ID: 2356768
[TBL] [Abstract][Full Text] [Related]
32. P50 abnormalities in schizophrenia: relationship to clinical and neuropsychological indices of attention.
Erwin RJ; Turetsky BI; Moberg P; Gur RC; Gur RE
Schizophr Res; 1998 Oct; 33(3):157-67. PubMed ID: 9789908
[TBL] [Abstract][Full Text] [Related]
33. Subtype diagnosis in schizophrenia and its relation to neuropsychological and computerized tomography measures.
Rosse RB; Schwartz BL; Mastropaolo J; Goldberg RL; Deutsch SI
Biol Psychiatry; 1991 Jul; 30(1):63-72. PubMed ID: 1892964
[TBL] [Abstract][Full Text] [Related]
34. The adenosine antagonist theophylline impairs p50 auditory sensory gating in normal subjects.
Ghisolfi ES; Prokopiuk AS; Becker J; Ehlers JA; Belmonte-de-Abreu P; Souza DO; Lara DR
Neuropsychopharmacology; 2002 Oct; 27(4):629-37. PubMed ID: 12377399
[TBL] [Abstract][Full Text] [Related]
35. P50 sensory gating in adolescents from a pacific island isolate with elevated risk for schizophrenia.
Myles-Worsley M; Ord L; Blailes F; Ngiralmau H; Freedman R
Biol Psychiatry; 2004 Apr; 55(7):663-7. PubMed ID: 15038993
[TBL] [Abstract][Full Text] [Related]
36. Disorders of smooth pursuit eye movement and auditory N100 in schizophrenic patients.
Strik WK; Dierks T; Böning J; Osterheider M; Caspari A; Körber J
Psychiatry Res; 1992 Mar; 41(3):227-35. PubMed ID: 1594709
[TBL] [Abstract][Full Text] [Related]
37. Evoked potential variation in schizophrenic subgroups.
Kessler C; Steinberg A
Biol Psychiatry; 1989 Aug; 26(4):372-80. PubMed ID: 2765600
[TBL] [Abstract][Full Text] [Related]
38. The P50 auditory event-evoked potential in adult attention-deficit disorder: comparison with schizophrenia.
Olincy A; Ross RG; Harris JG; Young DA; McAndrews MA; Cawthra E; McRae KA; Sullivan B; Adler LE; Freedman R
Biol Psychiatry; 2000 Jun; 47(11):969-77. PubMed ID: 10838065
[TBL] [Abstract][Full Text] [Related]
39. Amphetamine disrupts P50 suppression in normal subjects.
Light GA; Malaspina D; Geyer MA; Luber BM; Coleman EA; Sackeim HA; Braff DL
Biol Psychiatry; 1999 Oct; 46(7):990-6. PubMed ID: 10509182
[TBL] [Abstract][Full Text] [Related]
40. P50 changes with visual interference in normal subjects: a sensory distraction model for schizophrenia.
Jin Y; Potkin SG
Clin Electroencephalogr; 1996 Jul; 27(3):151-4. PubMed ID: 8828978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
